PGT-M (Monogenic)
Testing for single-gene disorders (e.g., Huntington's, Cystic Fibrosis)
Key Facts
About Carta Biosciences
Carta Biosciences, founded in 2018 and based in Cambridge, UK, is a private diagnostics company specializing in genomic testing for the IVF market. Its core innovation is a polygenic risk scoring (PGT-P) service, powered by a proprietary machine learning algorithm that analyzes whole-genome data to predict an embryo's lifetime risk for complex diseases like heart disease, diabetes, and breast cancer. The company integrates this with standard PGT tests (PGT-A, PGT-M, PGT-SR) into a single offering, aiming to give clinicians and parents a more comprehensive tool for embryo selection. Carta appears to be in an early commercial or late-development stage, targeting direct sales to IVF clinics.
View full company profile